For additional product information, please see
Press Release Details
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 20, 2022 at 4:05 PM EDT
Selected as a Featured Poster and ACR’s Ignite Talk is “Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy,” part of the core technology powering Exagen’s AVISE® RADR test development. In addition, data from Exagen’s research on machine learning in patients with fibromyalgia has been accepted for an oral presentation.
Exagen’s President and Chief Executive Officer,
Below is the list of accepted abstracts, with links to each:
Poster Presentation | Presented by
Title: Comparison of nCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
Session Time: 1:00 –
Featured Poster Presentation | Presented by
Title: Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to csDMARDs, Enriching csDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Session Title: RA – Treatment Poster II
Session Time: 9:00 –
Poster Presentation | Presented by
Title: Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations
Session Time: 1:00 –
Poster Presentation | Presented by
Title: Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Session Title: Fibromyalgia and Other Clinical Pain Syndromes Poster
Session Time: 1:00 –
Poster Presentation | Presented by Emily G Oaks | Abstract #1201
Title: Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms after COVID-19 Infection
Session Title: Epidemiology and Public Health Poster II
Session Time: 1:00 –
Poster Presentation | Presented by
Title: Stability of Cell Bound Complement Activation Products (CB-CAPS),
Session Title: Epidemiology and Public Health Poster III
Session Time: 1:00 –
Poster Presentation | Presented by
Title: Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients who will Respond or be Refractory to Standard Biological Treatments
Session Title: RA – Treatment Poster IV
Session Time: 1:00 –
Poster Presentation | Presented by
Title: The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE.
Session Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes
Session Time: 1:00 –
Oral Presentation | Presented by
Title: Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia
Session Title: Abstracts: Fibromyalgia and Other Clinical Pain Syndromes
Session Time: 4:30 –
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development team’s scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products or promoted therapeutics, including Exagen’s ability to collect funds due; expectations regarding its pipeline products, including the development of the AVISE® RADR platform; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations
rdouglas@exagen.com
760.560.1525
Company
kadawi@exagen.com
760.477.5514
Source: Exagen Inc.